Related references
Note: Only part of the references are listed.Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology
Antonella Tramutola et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2017)
Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology
Antonella Tramutola et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2017)
Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor
Ralph A. DeFronzo
DIABETES OBESITY & METABOLISM (2017)
Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models
Simone Renner et al.
JOURNAL OF PATHOLOGY (2016)
Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective
Francesco Zaccardi et al.
POSTGRADUATE MEDICAL JOURNAL (2016)
Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus
Onno N. Groeneveld et al.
JOURNAL OF DIABETES INVESTIGATION (2016)
IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes
Joao da Rocha Fernandes et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2016)
Glucose-Dependent Insulinotropic Peptide Stimulates Glucagon-Like Peptide 1 Production by Pancreatic Islets via Interleukin 6, Produced by α Cells
Katharina Timper et al.
GASTROENTEROLOGY (2016)
Beneficial metabolic actions of a stable GIP agonist following pre-treatment with a SGLT2 inhibitor in high fat fed diabetic mice
P. J. B. Millar et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2016)
Alzheimer's disease: Is this a brain specific diabetic condition?
Vanita Rani et al.
PHYSIOLOGY & BEHAVIOR (2016)
Future glucose-lowering drugs for type 2 diabetes
Clifford J. Bailey et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
Parkinson's Disease, Diabetes and Cognitive Impairment
Mohammad R. Ashraghi et al.
RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY (2016)
Dapagliflozin: A new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
Eva M. Vivian
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2015)
Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes
S. Matthaei et al.
DIABETES OBESITY & METABOLISM (2015)
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline
V. A. Gault et al.
DIABETES OBESITY & METABOLISM (2015)
Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function
Aurora Merovci et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes
Rachel Charlotte Moffett et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2015)
Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial
C. J. Bailey et al.
DIABETIC MEDICINE (2015)
Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
A. J. Scheen et al.
DIABETES & METABOLISM (2014)
Changes in Insulin Sensitivity and Insulin Secretion with the Sodium Glucose Cotransporter 2 Inhibitor Dapagliflozin
Sunder Mudaliar et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice
Rachael Lennox et al.
PEPTIDES (2014)
Incretin Receptor Null Mice Reveal Key Role of GLP-1 but Not GIP in Pancreatic Beta Cell Adaptation to Pregnancy
R. Charlotte Moffett et al.
PLOS ONE (2014)
Role of Endogenous GLP-1 and GIP in Beta Cell Compensatory Responses to Insulin Resistance and Cellular Stress
Srividya Vasu et al.
PLOS ONE (2014)
High fat diet feeding results in gender specific steatohepatitis and inflammasome activation
Michal Ganz et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties
Vikas K. Bhat et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice
T. Nagata et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Effects of LX4211, a Dual SGLT1/SGLT2 Inhibitor, Plus Sitagliptin on Postprandial Active GLP-1 and Glycemic Control in Type 2 Diabetes
Brian Zambrowicz et al.
CLINICAL THERAPEUTICS (2013)
Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice
W. D. Porter et al.
INTERNATIONAL JOURNAL OF OBESITY (2013)
High-fat feeding rapidly induces obesity and lipid derangements in C57BL/6N mice
Christine Podrini et al.
MAMMALIAN GENOME (2013)
A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation and Inflammation and Stimulates Neurogenesis in the APPswe/PS1ΔE9 Mouse Model of Alzheimer's Disease
Vadivel Parthsarathy et al.
PLOS ONE (2013)
Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats
Tiffany Schwasinger-Schmidt et al.
PHARMACOLOGICAL RESEARCH (2013)
Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
Jan Bolinder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats
James J. Devenny et al.
OBESITY (2012)
The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
Paula L. McClean et al.
JOURNAL OF NEUROSCIENCE (2011)
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
Helga Ellingsgaard et al.
NATURE MEDICINE (2011)
The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats
F. R. Macdonald et al.
DIABETES OBESITY & METABOLISM (2010)
Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet
V. A. Gault et al.
INTERNATIONAL JOURNAL OF OBESITY (2010)
Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease
Talib Abbas et al.
BEHAVIOURAL BRAIN RESEARCH (2009)
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
George L. Bakris et al.
KIDNEY INTERNATIONAL (2009)
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
Songping Han et al.
DIABETES (2008)
Diet-Induced Insulin Resistance Impairs Hippocampal Synaptic Plasticity and Cognition in Middle-Aged Rats
Alexis M. Stranahan et al.
HIPPOCAMPUS (2008)
Diabetes impairs hippocampal function through glucocorticoid-mediated effects on new and mature neurons
Alexis M. Stranahan et al.
NATURE NEUROSCIENCE (2008)
Accelerated cognitive aging in diabetic rats is prevented by lowering corticosterone levels
Alexis M. Stranahan et al.
NEUROBIOLOGY OF LEARNING AND MEMORY (2008)
Interleukin-6 regulates pancreatic α-cell mass expansion
Helga Ellingsgaard et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: Importance of fatty acid length, polarity, and bulkiness
Kjeld Madsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Increased number of islet-associated macrophages in type 2 diabetes
Jan A. Ehses et al.
DIABETES (2007)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
High-fat diets, insulin resistance and declining cognitive function
CE Greenwood et al.
NEUROBIOLOGY OF AGING (2005)
Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening
K Srinivasan et al.
PHARMACOLOGICAL RESEARCH (2005)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agerso et al.
DIABETOLOGIA (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Renal gluconeogenesis - Its importance in human glucose homeostasis
JE Gerich et al.
DIABETES CARE (2001)
Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration
LB Knudsen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)
Share Paper
